Biological therapies such as tumour necrosis factor (TNF), interleukin (IL) 12/23 and IL-17 and IL-23 inhibitors have revolutionised the treatment of moderate-to-severe psoriasis allowing many patients to achieve complete remission [4,5,6]. The gene discussed is IL17A; the disease is psoriasis.